Hesperidin suppressed metastasis, angiogenesis and tumour growth in Balb/c mice model of breast cancer

Considering the unfavourable response of breast cancer (BC) to treatment, we assessed the therapeutic potential hesperidin in mice bearing 4T1 BC tumours. Anti-tumour effects were assessed by measuring pathologic complete response (pCR), survival analysis, immunohistochemistry for E-cadherin, VEGF,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cellular and molecular medicine 2023-09, Vol.27 (18), p.2756-2769
Hauptverfasser:	Shakiba, Elham, Bazi, Ali, Ghasemi, Hamed, Gorji, Reza Eshaghi, Mehdipour, Seyyed Alireza, Nikfar, Banafsheh, Rashidi, Mohsen, Mirzaei, Sepideh
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Antitumor agents Breast cancer Cancer therapies CD105 antigen Chemotherapy Cyclooxygenase-2 Cytotoxicity Doxorubicin E-cadherin Flavonoids Gelatinase A Gelatinase B Gene expression Hesperidin Histopathology Immunohistochemistry Metastases Metastasis Original Stem cells Survival Synergism Tumors Vascular endothelial growth factor γ-Interferon
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Considering the unfavourable response of breast cancer (BC) to treatment, we assessed the therapeutic potential hesperidin in mice bearing 4T1 BC tumours. Anti-tumour effects were assessed by measuring pathologic complete response (pCR), survival analysis, immunohistochemistry for E-cadherin, VEGF, MMP9, MMP2 and Ki-67, serum measurement of IFNγ and IL-4, and gene expression analysis of CD105, VEGFa, VEGFR2 and COX2. Survival of tumour-bearing mice was the highest in mice receiving a combination of hesperidin and doxorubicin (Dox) (80%) compared to the normal saline (43%), hesperidin 5 (54%), 10 (55.5%), 10 (60.5%) and 40 (66%) mg/kg, and 10 mg/kg Dox-treated (73%) groups (p
ISSN:	1582-1838 1582-4934
DOI:	10.1111/jcmm.17902